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Data resource basics
The Prescribing Information System (PIS) provides an in-
frastructure for pharmacoepidemiology and pharmacovigi-
lance research, attracting growing attention due to its
unique combination of characteristics. Compared with
several databases worldwide offering national popula-
tion coverage and record linkage,1–3 PIS covers all
National Health Service (NHS) prescriptions prescribed,
dispensed and reimbursed within the community setting,
covering in Scotland a total population of 5.3 million
residents.
PIS provides summary information on reimbursed medi-
cines from 1993, and it also gives access to individual pre-
scribing and dispensing data since 2009 with the
incorporation in the system of a unique number, specific to
NHS Scotland, called the Community Health Index (CHI)
number (the PIS evolution process is shown in
Supplementary Figure 1, available as Supplementary data
at IJE online). Moreover, the presence of this number
allows the linkage of PIS data to other health records data,
thus describing a patient’s pathway through the healthcare
system. This dataset addresses the demand for longitudinal
data at a population level, captured through routine clin-
ical systems required to understand the chronology of drug
use and health outcomes, complementing the evidence gen-
erated through clinical trials and drug surveillance
schemes.4–6
Data resources and population coverage
PIS holds information for over 1.6 billion prescriptions
reimbursed in the community from January 1993 to 2014,
over 507 million items prescribed and over 344 million
items dispensed from 2009 to 2014.7 The CHI capture
rate, which shows the availability of patient-level data, is
almost 100% for the prescribed and dispensed items. Only
those with an invalid CHI are not included. For the reim-
bursed items, the rate has increased from 87.7% in 2009
up to 95.6% in 2014. In addition to items per patient, PIS
also covers information on active NHS prescribers and ap-
proximately 1200 community pharmacies. In the calendar
year of 2014, more than 70% of all men and 85% of all
women had one or more prescriptions reimbursed. The
proportion is similar in children (0–4 years) and people-
> 65 years old, regardless of gender. However, there is a
higher proportion of adult women in the population with
reimbursed prescriptions than men (Figure 1).
Data collected
Funding sources
PIS is an NHS data system and is funded from the public
monies available to the NHS. It is hosted within a national
information warehouse managed by NHS National
Services Scotland (NHS NSS). Current work to develop an
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improved PIS research-ready analysis platform is sup-
ported by the Farr Institute @ Scotland and its 10-funder
consortium. Research studies using PIS, as well as other
datasets, are funded by a variety of sources including the
Farr Institute, Chief Scientist Office, Medical Research
Councils and UK charities.
Dataset production
Figure 2 illustrates the sustainable journey of collecting,
prescribing and dispensing raw data at a population level
from three data sources—ePrescribed, eDispensed and
Reimbursed messages—which form the basis of PIS, and
the data available for the researcher community.
Prescriptions are written by a range of healthcare practi-
tioners including general practitioners (GPs), nurses,
dentists, pharmacists and an expanding range of other
non-medical prescribers. In all cases, a paper form is pro-
vided to the patient that they may take to the pharmacy of
their choice. In the case of GP prescribing, an electronic
prescription message (ePrescribed) is also generated and,
where this is the case, the dispensing pharmacist has the
option to also submit an electronic dispensed message
(eDispensed) to support the claim for reimbursement.
Once the prescription has been dispensed by the pharmacy
and collected by the patient, the paper forms are submitted
in monthly batches to NHS NSS for reimbursement.
Information from the paper form is captured by high-speed
scanners using optical character recognition, supplemented
by human operators. Where electronic messages also exist
for the prescription, then these act as the primary source of
information in preference to that captured by scanning.
The output from this process forms the reimbursed mes-
sage. As GPs account for more than 95% of prescribing in
primary care, the great majority of prescriptions processed
have at least one accompanying electronic source. Data ex-
tracts of PIS can be made available for researchers upon re-
quest, subject to relevant governance approval.
Frequency of data collection
Data generation takes place as part of routine prescribing
by health professionals and dispensing in the community
pharmacies in Scotland. The frequency of data generation
is determined by the needs and conditions of the patient,
but long-term repeat medicines are typically prescribed
and dispensed at 28- or 56-day intervals. Reimbursement
data are processed and loaded on a monthly cycle and are
available approximately 2 months after the prescription
was dispensed and collected by the patient. The
ePrescribed and eDispensed data are loaded daily and are
available 24 h and 14 days after the prescription was writ-
ten and dispensed, respectively.
Measures
Data variables included in PIS fall into four main catego-
ries: (i) patient-specific data; (ii) prescriber data; (iii) dis-
penser data; and (iv) drug data. More detailed information
about the PIS fields for researchers is available from the
Information Services Division Scotland website.8
Figure 1. Demographic characteristics of patients in PIS with a reimbursed prescription in 2014.
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Patient-specific data. Patients included in the database are
identified by their community health index (CHI) number.
As well as age and gender, CHI enables the prescription
record to be populated with data from the CHI national
register when requested. This register defines the patient’s
place of residence and indicates whether or not the patient
is in a care home. Geography-related information, such as
the Scottish Index of Multiple Deprivation (SIMD) ranking
and urban/rural classification, is also available.
Prescriber data. Prescribers have a unique identifier that
identifies the profession and the location where the
prescription was written. For GP practices, the number
and demographics of the registered patients is also
available.
Dispenser data. Each dispensing organization is assigned a
dispenser type, e.g. community pharmacy, and geographi-
cal location.
Drug data. For each reimbursed prescription, individual
variables describing the approved name (normally
International Nonproprietary Names (INN)), product
name, formulation and strength are available. Quantity
Figure 2. PIS prescribing, dispensing and reimbursed data from raw (2014) to researcher – ready access.
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information is available as number of tablets, etc., supplied
and also expressed in defined daily doses (DDDs).
Information is also available about instalment dispensing
and the number of instalments, including how many were
supervised (e.g. opiate substitution therapy). The database
captures information from the time the drug is prescribed
to the time (whether or not) it has been dispensed or reim-
bursed. Each drug product is also identifiable by an
extended BNF (British National Formulary) code.9 This is
a structured code that classifies medicines according to
therapeutic use as described in the BNF,10 and the
extended code differentiates between proprietary and
generic products and formulation and strength.
Drug data within ePrescribed and eDispensed messages
are expressed using codes and descriptions from the NHS
dictionary of medicines and devices (dmþd), which is a UK
extension of SNOMED-CT.11 In addition, electronic mes-
sages include the prescribed dose instructions, as free text,
and so these are also available for reimbursed prescriptions
for which an electronic message exists.
Data linkage
The CHI number is a unique numeric identifier, allocated
to each patient on first registration with the Scottish
healthcare datasets, but not social datasets. It is a 10-char-
acter code consisting of the 6-digit date of birth
(DDMMYY), two digits, a 9th digit which is always even
for females and odd for males and an arithmetical check
digit.12 The inclusion of this unique identifier in PIS allows
for accurate health data linkage at an individual level with
well-coded national and local databases, enabling studies
to be conducted across the entire lifespan of individuals
and populations. Further detail on the national databases
catalogue, including hospital records (SMR00 and
SMR01), maternal and neonatal records (SMR02), the
Scottish Cancer Registry (SMR06) and mortality records,
is available at [www.ndc.scot.nhs.uk]. Subject to approval
by the Public Benefit and Privacy Panel for Health and
Social Care (PBPP), other external datasets, e.g. clinical tri-
als, local health board data, disease registries and non-
health administrative data, can also be linked.
To comply with information governance procedures
and preserve patients’ confidentiality, the OECD
Guidelines on Human Biobanks and Genetic Research
Databases13 are followed and the electronic Data Research
and Innovation Service (eDRIS) team provides pseudo-ano-
nymized data extracts for researchers’ use. CHI numbers
are replaced by unique study numbers and personal identi-
fying information is removed. This is achieved in a secure
manner by having different teams handling patient
identifiers and study variables, and then performing the
linkage.14
Having national datasets with an outstanding quality of
recording events such as hospitalizations, surgical proce-
dures and underlying causes of mortality, record linkage
has successfully been carried out in Scotland in areas such
as diabetes.15 This goes along the same lines of successful
record-linkage programmes in the UK, done with other
data resources focusing on cardiovascular diseases, pri-
mary care and a subset of dispensed or prescribed prescrip-
tions in the population.16,17
Data resource use
PIS has the flexibility to be used as a stand-alone dataset or
connected to further datasets by using electronic record
linkage. Cohorts can either be identified according to the
type of drug/drug group of interest or patient groups can
be selected according to disease or other characteristics,
and using record linkage their prescriptions in primary
care can be studied. The possibility of creating groups is
not limited to those receiving a prescription or in PIS as, in
addition, matched (or unmatched) control groups—e.g.
from the CHI registry or other external datasets—can also
be created. Table 1 provides examples of studies conducted
using PIS, ranging from drug use to evaluation of drug
effects, guidance about drug prescribing and health eco-
nomics.18–37 By example, the knowledge generated from
PIS has already generated a change in the Scottish national
antibiotic policy recommendation for orthopaedic surgical
prophylaxis and has been used to evaluate interventions to
improve high-risk prescribing in primary care.19,20,29
Current developments
The FARR Institute @ Scotland, an NHS/academic collab-
oration, is enabling new datasets for research and
improved patient care including PIS, alongside a new
national GP primary care dataset (SPIRE), imaging (PACS
Images) and laboratory dataset (SCI-Store).38,39 The
investment in PIS is supporting improved drug coding and
connection to Anatomical Chemical Classification (ATC)
coding to support cross-national studies, as well as trans-
formation of drug dosage instructions into structured fields
to support the interpretation and quantification of drug
exposure and measurement of patient adherence. A proto-
type algorithm has been developed and tested in response
to the demand for drug dosage metadata.24
Further development is underway to apply the algo-
rithm to all prescription instructions held within PIS,
thereby enabling direct querying of data by drug dose, unit
and frequency of expected consumption. This work has
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supported a preferred partner status for future rapid phar-
macovigilance studies in collaboration with the European
Medicines Agency.
Strengths and weaknesses
Strengths
Coverage
The NHS in Scotland is a publicly-funded healthcare sys-
tem and is universally used by the 5.3 million people living
in Scotland. The dataset can be censored for death and
patients who have de-registered with the NHS in Scotland,
through linkage to other datasets. The NHS in Scotland
provides universal coverage; thus PIS is representative of
all age, sex and socioeconomic groups and geographies, is
free from any selection bias and allows for the detection of
rare events.
By the end of 2014, 95% of records captured included
the unique person identifier, and so data from PIS can be
accurately linked to a wide range of other health and non-
health datasets.
PIS is one of the few nationwide databases which
include routinely collected data on prescribed items and
whether they were dispensed and reimbursed or not.
This offers the possibility of studying treatment regimens
and their outcomes in the population, polypharmacy and
primary non-adherence although, in common with most
other prescription registries, there is no information about
when or whether the patient actually consumed the dis-
pensed medicine.
Another feature of its coverage is the availability of
drug dosage information, which is necessary for studies
with dose-dependent association between exposure and
effect.
Completeness
Prescriptions must be submitted for payment in order that
the dispenser can be reimbursed for the products supplied,
providing a strong incentive to do so. Data therefore have
a high level of completeness. However, although the avail-
ability of individual level data is high, this is influenced by
the type of health care practitioner prescribing and/or
service delivery models: in 2014, CHI capture by health-
care practitioner varied from 98.7% for GP prescribers to
1.6% for dentists; and for the same year, the CHI capture
rate of immunological products and vaccines was 71.5%
compared with 98.6% for cardiovascular medicines.
Table 1. Examples of projects by study type and extent of record linkage using PIS, 2009–15
Project title Drug
utilization
study
Effect
study
Health
economics
Other Linkage to
other
databases
Published
(P)/Ongoing (O)
Trends of utilization or enhancement to prescribe proton
pump inhibitors, statins, angiotensin receptor blockers
and antipsychotics21–23
 P
Factors influencing prescribing of antidepressants33  P
Burden of irritable bowel syndrome31  P
Primary care prescribing indicators28  P
Polypharmacy Guidance32  P
Prescribing of oral generic risperidone – findings across Europe26   P
Policies to enhance prescribing efficiency in Europe27  P
Socioeconomic deprivation and primary care antibiotic prescribing25  P
Reduction in broad-spectrum Gram-negative agents30   P
Risk of acute kidney injury with gentamicin as surgical prophylaxis20  P
Feedback to Improve Primary Care Prescribing Safety
(EFIPPS Study)19,29
  P
Opioid prescribing35  O
Methadone prescribing in Scotland24  O
Use of national, linked administrative health data to quantify the association
between antimicrobial prescription and Clostridium difficile infection:
a population based matched case control study (Unpublished)
   O
Impact on prescriptions and hospital admission of prescription
fee abolition in Scotland36
  O
The Greater Glasgow and Clyde Biologics Cohort18    O
Utilization, clinical effectiveness and safety of oral anticoagulants
and oral antiplatelets in Scotland34,37
    O
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Further data processing by researchers may be required
according to the completeness for specific studies.
Data quality
The capture by PIS of electronic prescription and dispens-
ing messages has resulted in an improvement in data qual-
ity by removing the majority of manual data entry
processes. In addition, the millions of raw records go
through more than 10 stages of quality checking before
and after they are submitted to PIS.40
Follow up
Longitudinal studies are feasible, both for cohorts and for
follow-up to clinical trials, thus enabling research about
use of medicines and healthcare resources in chronic condi-
tions as well as monitoring long-term outcomes.
Considering 2009 as the year in which CHI capture
increased, the present median follow-up is 6–7 years per
patient.
Weaknesses
Data not captured
PIS does not capture information about retail sales of over-
the-counter (OTC) medicines. It does however include sup-
plies of OTC medicines made to eligible individuals by
community pharmacists under the Minor Ailments Service
(MAS).41 Medicines administered during inpatient hospital
stays and upon discharge for short-term use, and some spe-
cialist drugs for chronic use such as biologicals and growth
hormone therapy are not captured, nor are outpatient sup-
plies made by the hospital service. Information about vac-
cines is variable: some of this is captured through an
alternative childhood immunization database.42
There is no information about diagnosis or indication
for treatment included on prescriptions, and so this infor-
mation is not available in PIS. Data from primary care
(SPIRE) may become available for linkage.39 In many cases
this limitation can be overcome by linkage to secondary
care or local datasets, and case identification can be opti-
mized with the corresponding algorithm as has been done
in other data resources.43,44
Data availability
More than 87% capture of the patient identifier was
achieved in 2009, but this figure falls away rapidly from
68% in 2008 to less than 1% in 2003. Therefore longitudi-
nal studies with PIS individual-level data are recommended
from 2009 onwards. PIS currently is suitable for most
research purposes; however, the processing lag and
variation in the frequency of data loads means that it is
unable to support real-time medication reconciliation
studies.
Data resource access
Researchers can access non-identifiable (but linkable) data
from PIS by contacting the eDRIS service run by NHS NSS
[www.isdscotland.org/Products-and-Services/eDRIS/].
Each research proposal is assigned an experienced research
coordinator who will guide the research team through the
selection of appropriate data items and any limitations
applicable to the proposed study, as well as guidance on
completion of the PBPP application process for approval to
link data. Once the requested data are approved by the
PBPP, data are extracted and provided to researchers
through personal accounts in national or local research
portals (safe havens) with secure access and storage.45,46
Currently PIS data are available to researchers based in rec-
ognized UK institutions. The PBPP can consider on a case-
by-case basis to provide data outside the UK. For more
information regarding application and costs, contact the
eDRIS team at [NSS.eDRIS@nhs.net].
Supplementary Data
Supplementary data are available at IJE online.
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Profile in a Nutshell
• In 2009, the Prescribing Information System (PIS)
was developed as a national individual-level dataset
of prescriptions prescribed, dispensed and reim-
bursed within the community setting in Scotland,
covering the 5.3 million residents.
• The dataset provides information about patient, pre-
scriber and dispenser characteristics, and the drugs
prescribed, dispensed and reimbursed (> 98% of the
items prescribed by general practitioners have indi-
vidual-level records).
• The availability of aggregated and patient-level data,
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linkable to a variety of local and national databases,
supports retrospective and prospective pharmacoe-
pidemiological studies at different levels of
complexity.
• Evolving PIS developments (including enhanced
drug coding and interpretable dose instructions) will
provide better intelligence on the safety and effec-
tiveness of medicines in routine clinical practice.
• Data are available upon request to the electronic
Data Research and Innovation Service
[NSS.eDRIS@nhs.net].
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